Skip to content

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada.

Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 200 participants will be enrolled in the study in approximately 15-20 sites in Canada.

Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Diagnosis of Acute Myeloid Leukemia (AML).
* Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice.
* Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.

Exclusion Criteria:

- Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Lieu de l'étude

BC Cancer - Surrey /ID# 257515
BC Cancer - Surrey /ID# 257515
Surrey, British Columbia
Canada

Contactez l'équipe d'étude

The Moncton Hospital /ID# 247277
The Moncton Hospital /ID# 247277
Moncton, New Brunswick
Canada

Contactez l'équipe d'étude

Kingston Health Sciences Centre /ID# 253439
Kingston Health Sciences Centre /ID# 253439
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Sunnybrook Health Sciences Ctr /ID# 251966
Sunnybrook Health Sciences Ctr /ID# 251966
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Allan Blair Cancer Centre /ID# 247663
Allan Blair Cancer Centre /ID# 247663
Regina, Saskatchewan
Canada

Contactez l'équipe d'étude

University of Alberta Hospital /ID# 251531
University of Alberta Hospital /ID# 251531
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

CancerCare Manitoba /ID# 246414
CancerCare Manitoba /ID# 246414
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Juravinski Cancer Centre /ID# 247183
Juravinski Cancer Centre /ID# 247183
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Site Coordinator

9055212100
Thunder Bay Regional Research Institute /ID# 249163
Thunder Bay Regional Research Institute /ID# 249163
Thunder Bay, Ontario
Canada

Contactez l'équipe d'étude

CIUSSS de l'Estrie - CHUS /ID# 248915
CIUSSS de l'Estrie - CHUS /ID# 248915
Sherbrooke, Quebec
Canada

Contactez l'équipe d'étude

Vancouver General Hospital /ID# 245438
Vancouver General Hospital /ID# 245438
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Eastern Regional Health Authority /ID# 250241
Eastern Regional Health Authority /ID# 250241
St. John's, Newfoundland and Labrador
Canada

Contactez l'équipe d'étude

London Health Sciences Center- University Hospital /ID# 248027
London Health Sciences Center- University Hospital /ID# 248027
London, Ontario
Canada

Contactez l'équipe d'étude

Princess Margaret Cancer Centre /ID# 249607
Princess Margaret Cancer Centre /ID# 249607
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Saskatoon Cancer Centre /ID# 247181
Saskatoon Cancer Centre /ID# 247181
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Tom Baker Cancer Centre /ID# 248113
Tom Baker Cancer Centre /ID# 248113
Calgary, Alberta
Canada

Contactez l'équipe d'étude

BC Cancer - Victoria /ID# 257339
BC Cancer - Victoria /ID# 257339
Victoria, British Columbia
Canada

Contactez l'équipe d'étude

QEII - Health Sciences Centre /ID# 246514
QEII - Health Sciences Centre /ID# 246514
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

Lakeridge Health - Oshawa /ID# 246412
Lakeridge Health - Oshawa /ID# 246412
Oshawa, Ontario
Canada

Contactez l'équipe d'étude

Royal Victoria Hospital / McGill University Health Centre /ID# 249704
Royal Victoria Hospital / McGill University Health Centre /ID# 249704
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
AbbVie
Participants recherchés
Plus d'informations
ID de l'étude: NCT05424562